- Home
- FTHM vs NRSN Comparison
FTHM vs NRSN Comparison
Compare FTHM & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FTHM | NRSN |
|---|---|---|
| Founded | 2010 | 2017 |
| Country | United States | Israel |
| Employees | N/A | 16 |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.5M | 26.5M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | FTHM | NRSN |
|---|---|---|
| Price | $0.82 | $0.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $2.50 | ★ $8.50 |
| AVG Volume (30 Days) | ★ 154.9K | 148.5K |
| Earning Date | 05-12-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.71 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $420,477,000.00 | N/A |
| Revenue This Year | $11.67 | N/A |
| Revenue Next Year | N/A | $583.67 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 25.45 | N/A |
| 52 Week Low | $0.48 | $0.63 |
| 52 Week High | $3.37 | $2.60 |
Technical Indicators
Market Signals| Indicator | FTHM | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 43.57 | 62.26 |
| Support Level | $0.70 | $0.85 |
| Resistance Level | $0.85 | $1.06 |
| Average True Range (ATR) | 0.10 | 0.06 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 1.31 | 70.13 |
Price Performance
Historical ComparisonAbout FTHM Fathom Holdings Inc.
Fathom Holdings Inc is a national, technology-driven, real estate services platform integrating residential brokerage, mortgage, title, insurance, and Software as a Service (SaaS) offering to brokerages and agents by leveraging proprietary cloud-based software, intelliAgent. The company has three reportable segments namely Real Estate Brokerage, Mortgage and Technology. The brands of the company include Fathom Realty, Dagley Insurance, Encompass Lending, intelliAgent, LiveBy, Real Results, and Verus Title. Majority of revenue is from Real Estate segment.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.